

Literatura ACTA MEDICINAE 16/2021 Farmakologická léčba

- 2 **Farmakologická léčba srdečního selhání – současné možnosti a výhledy do blízké budoucnosti**
prof. MUDr. Filip Málek, Ph.D., MBA Komplexní kardiologické centrum Nemocnice Na Homolce, Praha
- 2 **Hypolipidemika – současnost a výhledy**
MUDr. Stanislav Šimek, Ph.D. Fyziologický ústav 1. LF UK, Kardiologie Bulovka, s. r. o., Kardiologie Vinohrady, s. r. o., Praha
- 2 **Valsartan: možnosti preskripce v ordinaci praktického lékaře**
MUDr. Jiří Krupička, Ph.D. | MUDr. Pavel Franc | MUDr. Robin Králík Kardiologická a interní ambulance, MEDICUS SERVICES, s. r. o., Brandýs nad Labem
- 2 **Význam idarucizumabu jakožto antidota u dabigatranem léčených osob**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 3 **Farmakologická léčba srdečního selhání se sníženou ejekční frakcí dle nových ESC guidelines 2021 – reportáž z internistického kongresu**
- 3 **Současná farmakoterapie obezity**
MUDr. Petra Šrámková OB klinika, a. s., Centrum pro léčbu obezity a metabolických poruch, Praha
- 3 **Blíží se doba bezalzheimerovská?**
doc. MUDr. Roman Jiráček, CSc. Psychiatrická klinika, 1. LF UK a VFN, Praha
- 3 **Desodrop – profil zdravotnického prostředku**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Trelegy – ovlivnění mortality při léčbě chronické obstrukční plicní nemoci. Sekundární analýza studie IMPACT**
MUDr. Jaromír Zatloukal, Ph.D. Klinika plicních nemocí a TBC, FN a LF UP, Olomouc
- 4 **siRNA jako nový terapeutický nástroj**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Cílená léčba karcinomu plic**
MUDr. Juraj Kultán Klinika plicních nemocí a TBC, FN a LF UP, Olomouc
- 5 **Entrectinib v léčbě ROS1 pozitivního pokročilého nemalobuněčného plicního karcinomu a v léčbě solidních nádorů s NTRK fúzí**
MUDr. Petra Zemanová Onkologická klinika, Klinika tuberkulózy a respiračních onemocnění VFN a 1. LF UK, Praha
doc. MUDr. Milada Zemanová, Ph.D. | prof. MUDr. Luboš Petruželka, CSc. | MUDr. Jan Špaček, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha doc. MUDr. Jiří Votruba, Ph.D. Klinika tuberkulózy a respiračních onemocnění VFN a 1. LF UK, Praha
- 6 **Leuprorelin v léčbě karcinomu prostaty**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 6 **Sorafenib STADA 400 mg potahované tablety – lékový profil**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 6 **Niraparib – zaměřeno na efektivní dávkování – souhrnné sdělení**
MUDr. Josef Chovanec, Ph.D. | MUDr. Monika Náležinská Oddělení gynekologické onkologie, Klinika operační onkologie MOÚ a LF MU Brno
- 6 **Lipozomálně vázaný irinotekan v onkologické léčbě**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 7 **Belantamab mafodotin, první protilátka konjugovaná s cytotoxickou látkou pro léčbu mnohočetného myelomu**
MUDr. Zdeněk Kořístek, Ph.D. Klinika hematologie, Fakultní nemocnice Ostrava
- 7 **Inovativní přístupy v léčbě atopické dermatitidy – méně specifická cílená léčba, nebo biologická léčba „šitá na míru“?**
prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA Dermatovenerologická klinika FN KV, Praha

Farmakologická léčba srdečního selhání – současné možnosti a výhledy do blízké budoucnosti

prof. MUDr. Filip Málek, Ph.D., MBA Komplexní kardiologické centrum Nemocnice Na Homolce, Praha

- 1 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2021, 42, s. 3599–3726.
- 2 Anker, S. D. – Butler, J. – Filippatos, G., et al.: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, doi: 10.1056/NEJMoa2107038.

Další literatura u autora.

Hypolipidemika – současnost a výhledy

MUDr. Stanislav Šimek, PhD. Fyziologický ústav 1. LF UK, Kardiologie Bulovka, s. r. o., Kardiologie Vinohrady, s. r. o., Praha

- 1 Erlinge, D. – Maehara, A. – Ben-Yehuda, O., et al.: Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. *Lancet*, 2021, 397, s. 985–995.
- 2 Mach, F. – Baigent, C. – Catapano, A. L., et al.: Authors/Task Force Members 2019: ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J*, 2020, 41, s. 32, 111–188.
- 3 Boren, J. – Chapman, M. J. – Krauss, R. M., et al.: Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*, 2020, 41, s. 2313–2330.
- 4 Balling, M. – Afzal, S. – Varbo, A., et al.: VLDL Cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. *J Am Coll Cardiol*, 2020, 76, s. 2725–2735.
- 5 Christopher, P. – Cannon, C. P. – Blazing, M. A., et al.: IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.
- 6 Šatný, M. – Vrablík, M.: Desatero použití ezetimibu aneb stručný průvodce jeho použitím v současnosti. *Athero Rev*, 2019, 4, s. 161–165.
- 7 Schwartz, G. G. – Steg, P. G. – Szarek, M., et al.: ODYSSEY OUTCOMES Committees and Investigators: Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*, 2018, 379, s. 2097–2107.
- 8 Sabatine, M. S. – Giugliano, R. P. – Wiviott, S. D., et al.: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1500–1509.
- 9 Gao, F., et al.: Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography. *Lipids in Health and Disease*, 2021, 20, s. 106.
- 10 Vrablík, M. – Prusikova, M. – Snejdrlova, M., et al.: Omega-3 fatty acids and cardiovascular disease risk: do we understand the relationship? *Physiol Res*, 2009, 58, suppl. 1, s. S19–S26.
- 11 Hoy, S. M.: Pitavastatin: a review in hypercholesterolemia. *Am J Cardiovasc Drugs*, 2017, 17, s. 157–168.
- 12 Laufs, U. – Banach, M. – Mancini, G. B.: Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. *J Am Heart Assoc*, 2019, 8, s. e011662.
- 13 Khan, S. U. – Michos, E. D.: Bempedoic acid and ezetimibe – better together. *Eur J Prev Cardiol*, 2020, 27, s. 590–592.
- 14 Vogt, A.: Lipoprotein(a)-antisense therapy. *Clin Res Cardiol*, 2019, 14, suppl. 1, s. 51–56.
- 15 Warden, B. A. – Duell, P. B.: Volanesorsen for treatment of patients with familial chylomicronemia syndrome. *Drugs Today*, 2018, 54, s. 721–735.
- 16 Raal, F. J. – Rosenson, R. S. – Reeskamp, L. F.: Evinacumab for homozygous familial hypercholesterolemia. *N Engl J Med*, 2020, 383, s. 711–720.
- 17 Ray, K. K. – Landmesser, U. – Leiter, L. A., et al.: Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. *N Engl J Med*, 2017, 376, s. 1430–1440.
- 18 Ray, K. K. – Wright, R. S. – Kallend, D., et al.: ORION-10 and ORION-11 Investigators: Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med*, 2020, 382, s. 1507–1519.
- 19 Fruchart, J. C. – Santos, R. D. – Aguilar-Salinas, C., et al.: The selective peroxisome proliferator-activated receptor alpha modulator (SP-PARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. *Cardiovasc Diabetol*, 2019, 18, s. 71.
- 20 Scott, L. J.: Alipogene tiparovvec: a review of its use in adults with familial lipoprotein lipase deficiency. *Drugs*, 2015, 75, s. 175–182.
- 21 Alonso, R. – Cuevas, A. – Mata, P.: Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid*, 2019, 14, s. 19–30.

Valsartan: možnosti preskripce v ordinaci praktického lékaře

MUDr. Jiří Krupička, Ph.D. | MUDr. Pavel Franc | MUDr. Robin Králík Kardiologická a interní ambulance, MEDICUS SERVICES, s. r. o., Brandýs nad Labem

- 1 Švihovec, J., et al.: *Farmakologie*. Grada, Praha, 2018.
- 2 Smith, D.: Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. *Drugs*, 2008, 68, s. 1207–1225.
- 3 Widimský, J., jr. et al.: *Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017*.
- 4 Bakris, G. L.: The evolution of treatment guidelines for diabetic nephropathy Strategies integrate JNC VI, more recent protocols. *Postgrad Med*, 2003, 113, s. 35–40.
- 5 Pitt, B. – Segal, R. – Martinez, F. A., et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet*, 1997, 349, s. 747–752.
- 6 Pitt, B. – Poole-Wilson, P. A. – Segal, R., et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. *Lancet*, 2000, 355, s. 1582–1587.
- 7 Cohn, J. N.: Lessons learned from the valsartan – heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. *Am J Cardiol*, 2002, 90, s. 992–993.
- 8 Dickstein, K.: ELITE II and Val-HeFT are different trials: together what do they tell us? *Curr Control Trials Cardiovasc Med*, 2001, 2, s. 240–243.
- 9 Pfeffer, M. A. – Swedberg, K. – Granger, C. B., et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*, 2003, 362, s. 759–766.
- 10 Pfeffer, M. A. – McMurray, J. J. – Velazquez, E. J., et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*, 2003, 349, s. 1893–1906.
- 11 Yusuf, S. – Teo, K. K. – Pogue, J., et al.: for the ONTARGET investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*, 2008, 358, s. 1547–1559.
- 12 Dahlöf, B. – Devereux, R. B. – Kjeldsen, S. E., et al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*, 2002, 359, s. 995–1003.
- 13 Pěnička, M. – Gregor, P. – Kerekes, R., et al.: for the Candesartan use in Hypertrophic And Nonobstructive Cardiomyopathy Estate (CHANCE) Study Investigators: The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: A pilot, randomized study. *JMD*, 2009, 11, s. 35–41.
- 14 Kjeldsen, J. S. – Weber, M. – Brunner, H. R.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*, 2004, 363, s. 2022–2031.
- 15 Lindholm, L. H.: Valsartan treatment of hypertension – does VALUE add value? *Lancet*, 2004, 363, s. 2010–2011.
- 16 Papademetriou, V. – Farsang, C. – Elmfield, D., et al.: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). *J Am Coll Cardiol*, 2004, 44, s. 1175–1180.
- 17 McMurray, J. J. – Packer, M. – Desai, A. S., et al.: PARADIGM-HF Investigators and Committees: Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004.
- 18 McMurray, J. J. – Packer, M. – Desai, A. S., et al.: on behalf of the PARADIGM-HF Investigators and Committees: Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004.

Význam idarucizumabu jakožto antidota u dabigatranem léčených osob

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Kermer, P. – Eschenfelder, C. C. – Diener, H. C., et al.: Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – Updated series of 120 cases. *Int J Stroke*, 2020, 15, s. 609–618.
- 2 Pollack, C. V. Jr. – Reilly, P. A. – van Ryn, J., et al.: Idarucizumab for dabigatran reversal – full cohort analysis. *N Engl J Med*, 2017, 377, s. 431–441.
- 3 Idarucizumab Overview, dostupné z: <https://www.creativebiolabs.net/idarucizumab-overview.htm>, vyhledáno 17. 11. 2021.
- 4 Praxbind, EMEA/H/C/003986-N/0024, dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/praxbind>, vyhledáno 17. 11. 2021.
- 5 Thibault, N. – Morrill, A. M. – Willett, K. C.: Idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review. *Am J Ther*, 2018, 25, s. e333–e338.
- 6 Glund, S. – Moschetti, V. – Norris, S., et al.: A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. *Thromb Haemost*, 2015, 113, s. 943–951.
- 7 Diener, H. C. – Bernstein, R. – Butcher, K., et al.: Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischaemic stroke: Expert opinion. *Int J Stroke*, 2017, 12, s. 9–12.
- 8 Steffel, J. – Verhamme, P. – Potpara, T. S., et al.: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. *Europace*, 2018, 20, s. 1231–1242.
- 9 Ntaios, G. – Papavasileiou, V. – Diener, H. C., et al.: Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. *Int J Stroke*, 2017, 12, s. 589–596.
- 10 Ruff, C. T. – Giugliano, R. P. – Braunwald, E., et al.: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*, 2014, 383, s. 955–962.
- 11 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S., et al.: Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2009, 361, s. 1139–1151.
- 12 Jin, C. – Huang, R. J. – Peterson, E. D., et al.: Intravenous tPA (Tissue-Type Plasminogen Activator) in patients with acute ischemic stroke taking non-vitamin K antagonist oral anticoagulants preceding stroke. *Stroke*, 2018, 49, s. 2237–2240.

- 13 Giustozzi, M. – Verso, M. – Agnelli, G., et al.: Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. *J Thromb Thrombolysis*, 2017, 44, s. 527–535.
- 14 Vene, N. – Mavri, A. – Božič-Mijovski, M., et al.: Idarucizumab for dabigatran reversal in daily clinical practice: A case series. *Eur J Anaesthesiol*, 2020, 37, s. 874–878.
- 15 Frol, S. – Sagris, D. – Pretnar Oblak, J., et al.: Intravenous thrombolysis after dabigatran reversal by idarucizumab: a systematic review of the literature. *Front Neurol*, 2021, 12, s. 666086.

Farmakologická léčba srdečního selhání se sníženou ejekční frakcí dle nových ESC guidelines 2021 – reportáž z internistického kongresu

- 1 Lopez, A. – Adair T.: Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. *Int J Epidemiol*, 2019, 48, s. 1815–1823, <https://doi.org/10.1093/ije/dyz143>.
- 2 Lim, S. S. – Vos, T. – Flaxman, A. D., et al.: A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*, 2012, 380, s. 2224–2260.
- 3 Grover, S. A. – Coupal, L. – Kouache, M., et al.: Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia? *Can J Cardiol*, 2007, 23, s. 467–473.
- 4 Guidelines ESC 2021 pro HFREF.

Současná farmakoterapie obezity

MUDr. Petra Šrámková OB klinika, a. s., Centrum pro léčbu obezity a metabolických poruch, Praha

- 1 Stav obezity v České republice. Výsledky průzkumu STEM/MARK a VZP 2013. Dostupné z: <https://www.sliedshare.net/stemmark/obezita-2013-stemmark-vzp>, vyhledáno 10. 10. 2021.
- 2 COVID-19 and Obesity: The 2021. Atlas. Dostupné z: <https://www.worldobesity.org/resources/resource-library/covid-19-and-obesity-the-2021-atlas>, vyhledáno 10. 10. 2021.
- 3 Svačina, Š.: *Obezitologie a teorie metabolického syndromu. Lékařské repertorium*. Praha, Triton, 2013, s. 33–40.
- 4 Apovian, C. M.: The obesity epidemic – understanding the disease and the treatment. *N Engl J Med*, 2016, 374, s. 177–179.
- 5 Harrison, P.: Obesity is a disease, not a choice (experts advise). Dostupné z: <https://www.medscape.com/viewarticle/896444>, vyhledáno 10. 10. 2021.
- 6 Cefalu, T., et al.: Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors' expert forum. *Diabetes Care*, 2015, 38, s. 1567–1582.
- 7 Hainer, V., et al.: *Základy klinické obezitologie*. Praha, Grada, 2011, s. 277–280.
- 8 Billes, S. K. – Sinnayah, P. – Cowley, M. A.: Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. *Pharmacol Res*, 2014, 84, s. 1–11.
- 9 Greenway, F. L., et al.: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2010, 376, s. 595–605.
- 10 Wadden, T. A., et al.: Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial. *Obesity*, 2011, 19, s. 110–120.
- 11 Hollander, P. – Gupta, A. K. – Plodkowski, R., et al.: Effects of naltrexone sustained-release / bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. *Diabetes Care*, 2013, 36, s. 4022–4029.
- 12 Nissen, S. E., et al.: Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors, a randomized clinical trial. *JAMA*, 2016, 315, s. 990–1004.
- 13 Flint, A. – Raben, A. – Ersbøll, A. K., et al.: The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. *Int J Obes Relat Metab Disord*, 2001, 25, s. 781–792.
- 14 Deacon, C. F. – Nauck, M. A. – Toft-Nielsen, M., et al.: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. *Diabetes*, 1995, 44, s. 1126–1131.
- 15 Astrup, A. – Carraro, R. – Finer, N., et al.: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. *Int J Obes*, 2012, 36, s. 843–854.
- 16 Wadden, T. A., et al.: Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. *Obesity*, 2019, 27, s. 75–86.
- 17 Pi-Sunyer, X. – Astrup, A. – Fujioka, K., et al.: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*, 2015, 373, s. 11–22.
- 18 Marso, S. P., et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2016, 375, s. 311–322.
- 19 Saxenda, liraglutide. EMA/CHMP/172820/2021. Committee for Medicinal Products for Human Use (CHMP). Dostupné z: [ema.europa.eu/en/documents/smp/chmp-post-authorisation-summary-positive-opinion-saxenda-ii-26_en.pdf](https://www.ema.europa.eu/en/documents/smp/chmp-post-authorisation-summary-positive-opinion-saxenda-ii-26_en.pdf), vyhledáno 10. 10. 2021.
- 20 Kelly, A. S., et al.: A randomized, controlled trial of liraglutide for adolescents with obesity. *N Engl J Med*, 2020, 382, s. 2117–2128.
- 21 Torgerson, J. S. – Hauptman, J. – Boldrin, M. N., et al.: Xenical in the prevention of diabetes in obese subject (XENDOS) study: randomized study of orlistat as an adjunct to lifestyle changes for prevention of type 2 diabetes in obese subjects. *Diabetes Care*, 2004, 27, s. 155–161.
- 22 Gadde, K. M. – Allison, D. B. – Ryan, D. H., et al.: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet*, 2011, 377, s. 1341–1352.
- 23 O'Neil, P. M., et al.: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet*, 2018, 392, s. 637–649.
- 24 Enebo, L. B. – Berthelsen, K. K. – Kankam, M., et al.: Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. *Lancet*, 2021, 397, s. 1736–1748.
- 25 Bays, H. E., et al.: Licoglitazone, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity. *Obesity*, 2020, 28, s. 870–881.

Blíží se doba bezalzheimerovská?

doc. MUDr. Roman Jiráček, CSc. Psychiatrická klinika, 1. LF UK a VFN, Praha

- 1 Congdon, E. E. – Sigurdsson, E. M.: Tau-targeting therapies for Alzheimer disease. *Nat Rev Neurol*, 2018, 4, s. 399–415.
- 2 Cummings, J. – Tong, G. – Ballard, C.: Treatment combinations for Alzheimer's disease: current and future pharmacotherapy options. *J Alzheimers Dis*, 2019, 67, s. 779–794.
- 3 Folch, J. – Petrov, D. – Ettchet, M., et al.: Current research therapeutic strategies for Alzheimer's disease treatment. *Neural Plasticity*, 2016, ID 8501693.
- 4 Jadhav, S. – Avila, J. – Schöhl, M., et al.: A walk through tau therapeutic strategies. *Acta Neuropathol Commun*, 2019, 7, 22, dostupné z: <https://doi.org/10.1186/s40478-019-0664-z>, vyhledáno 15. 10. 2021.
- 5 Maia, M. – Sousa, E.: Bace-1 and gamma-secretase as therapeutic targets for Alzheimer's disease. *Pharmaceuticals*, 2019, 12, s. 41.
- 6 Manzano, S. – Agüera, L. – Aguilar, M., et al.: A review of tramiprosate (Homotaurine) in Alzheimer's disease and other neurocognitive disorders. *Front Neurol*, 2020, doi.org/10.3389/fneur.2020.00614.
- 7 Mintun, M. A. – Lo, A. C. – Duggan Evans, C., et al.: Donanemab in EARLY Alzheimer's disease. *N Engl J Med*, 2001, 384, s. 1691–1704.
- 8 Novak, P. – Kovacech, B. – Katina, S., et al.: ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. *Nat Aging*, 2021, 1, s. 521–534.
- 9 Schneider, L. S. – Geffen, Y. – Rabinowitz, J., et al.: Ladostigil Study Group: Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. *Neurology*, 2019, 93, s. e1474–e1484.
- 10 Selkoe, D.: β -secretase inhibitors for Alzheimer's disease: heading in the wrong direction? *Lancet Neurol*, 2019, 18, s. 624–626.
- 11 Tsoikai, M.: Future strategies of management of Alzheimer's Disease. The role of homotaurine. *Hell J Nucl Med*, 2019, 22, suppl., s. 82–94.

Desodrop – profil zdravotnického prostředku

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Ugazio, E. – Tullio, V. – Binello, A., et al.: Ozonated oils as antimicrobial systems in topical applications: Their characterization, current applications, and advances in improved delivery techniques. *Molecules*, 2020, 25, s. 334.
- 2 Celenza, G. – Iorio, R. – Cracchiolo, S., et al.: Antimycotic activity of ozonized oil in liposome eye drops against *Candida* spp. *Transl Vis Sci Technol*, 2020, 9, s. 4.
- 3 Paduch, R. – Urbanik-Sypniewska, T. – Kutkowska, J., et al.: Ozon-based eye drops activity on ocular epithelial cells and potential pathogens infecting the front of the eye. *Antioxidants*, 2021, 10, s. 968.
- 4 Rizzo, S. – Savastano, M. C. – Bortolotti, D., et al.: COVID-19 ocular prophylaxis: the potential role of ozonated-oils in liposome eyedrop gel. *Transl Vis Sci Technol*, 2021, 10, s. 7.
- 5 Marchegiani, A. – Magagnini, M. – Cerquetella, M., et al.: Preoperative topical liposomal ozone dispersion to reduce bacterial colonization in conjunctival sac and periocular skin: Preliminary study in dogs. *Exp Eye Res*, 2019, 189, s. 107848.
- 6 Passidomo, F. – Pignatelli, F. – Addabbo, G. – Costagliola, C.: Topical liposomal ozonated oil in complicated corneal disease: a report on three clinical cases. *Int Med Case Rep J*, 2021, 14, s. 327–332.
- 7 Cutarelli, A. – Carlin, G. – Sarno, F., et al.: The role of ozone carried by liposomes in the therapy of infectious and skin-regenerating ocular surface. *J Biomedical Science and Engineering*, 2019, 12, s. 347–353.
- 8 Spadea, L. – Zanotto, E. – Cavallo, R., et al.: ELOOM Study Investigators: Effectiveness of liposomal ozonised oil in reducing ocular microbial flora in patients undergoing cataract surgery. *J Cataract Refract Surg*, 9. 4. 2021, publikováno před tiskem.

Trelegy – ovlivnění mortality při léčbě chronické obstrukční plicní nemoci. Sekundární analýza studie IMPACT

MUDr. Jaromír Zatloukal, Ph.D. Klinika plicních nemocí a TBC, FN a LF UP, Olomouc

- Lipson, D. A. – Barnhart, F. – Brealey, N., et al.: IMPACT Investigators: Once-daily single-inhaler triple versus dual therapy in patients with COPD. *N Engl J Med*, 2018, 378, s. 1671–1680.
- Lipson, D. A. – Crim, C. – Criner, G. J., et al.: Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2020, 201, s. 1508–1516.
- Anthonisen, N. R. – Skeans, M. A. – Wise, R. A., et al.: Lung Health Study Research Group: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med*, 2005, 142, s. 233–239.
- Bez uvedení autorství: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. *Ann Intern Med*, 1980, 93, s. 391–398.
- Bez uvedení autorství: Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Report of the Medical Research Council Working Party*, 1981, 1, s. 681–686.
- Fishman, A. – Martinez, F. – Naunheim, K., et al.: National Emphysema Treatment Trial Research Group: A randomized trial comparing lung lung volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med*, 2003, 348, s. 2059–2073.
- Calverley, P. M. A. – Anderson, J. A. – Celli, B., et al.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med*, 2007, 356, s. 775–789.
- Wedzicha, J. A. – Calverley, P. M. – Seemungal, T. A., et al.: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med*, 2008, 177, s. 19–26.
- Celli, B. – Decramer, M. – Kesten, S., et al.: UPLIFT Study Investigators: Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2009, 180, s. 948–955.
- Vestbo, J. – Anderson, J. A. – Brook, R. D., et al.: Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): double-blind randomised controlled trial. *Lancet*, 2016, 387, s. 1817–1826.
- Lee, H. W. – Park, J. – Jo, J., et al.: Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. *PLoS Med*, 2019, 16, s. e1002958.

siRNA jako nový terapeutický nástroj

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- Anguela, X. M. – High, K. A.: Entering the modern era of gene therapy. *Annu Rev Med*, 2019, 70, s. 273–288.
- Setten, R. L. – Rossi, J. J. – Han, S. P.: The current state and future directions of RNAi-based therapeutics. *Nat Rev Drug Discov*, 2019, 18, s. 421–446.
- Napoli, C. – Lemieux, C. – Jorgensen, R.: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. *Plant Cell*, 1990, 2, s. 279–289.
- Elbashir, S. M. – Harborth, J. – Lendeckel, W., et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*, 2001, 411, s. 494–498.
- Cho, W. G. – Albuquerque, R. J. – Kleinman, M. E., et al.: Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. *Proc Natl Acad Sci U S A*, 2009, 106, s. 7137–7142.
- Jayaraman, M. – Ansell, S. M. – Mui, B. L., et al.: Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. *Angew Chem Int Ed Engl*, 2012, 51, s. 8529–8533.
- Wittrup, A. – Lieberman, J.: Knocking down disease: a progress report on siRNA therapeutics. *Nat Rev Genet*, 2015, 16, s. 543–552.
- Hu, B. – Zhong, L. – Weng, Y., et al.: Therapeutic siRNA: state of the art. *Signal Transduct Target Ther*, 2020, 5, s. 101.

Cílená léčba karcinomu plic

MUDr. Juraj Kultán Klinika plicních nemocí a TBC, FN a LF UP, Olomouc

- Travis, W. D. – Brambilla, E. – Nicholson, A. G., et al.: The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol*, 2015, 10, s. 1243–1260.
- Ferlay, J. – Colombet, M. – Soerjomataram, I., et al.: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer*, 2018, 103, s. 356–387.
- Russo, A. – Franchina, T. – Ricciardi, G. R., et al.: A decade of EGFR inhibition in EGFR-mutated non-small-cell lung cancer (NSCLC): Old successes and future perspectives. *Onco Target*, 2015, 6, s. 26814–26825.
- Wintheiser, G. A. – Silberstein, P.: Physiology, tyrosine kinase receptors. *Stat Pearls*, 1. 10. 2021.
- König, D. – Savic Prince, S. – Rothschild, S. I.: Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. *Cancers*, 2021, 13, s. 804.
- Steuer, C. E. – Behera, M. – Berry, L., et al.: Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. *Cancer*, 2016, 122, s. 766–772.
- Kerr, K. M. – Bibeau, F. – Theunissen, E., et al.: The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. *Lung Cancer*, 2021, 154, s. 161–175.
- Grosse, A. – Grosse, C. – Rechsteiner, M., et al.: Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland. *Diagn Pathol*, 2019, 14, s. 18.
- Hantson, I. – Dooms, C. – Verbeken, E., et al.: Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. *Translational Respiratory Medicine*, 2014, 2, s. 9. DOI:10.1186/s40247-014-0009-0.
- Sacher, A. G. – Dahlberg, S. E. – Heng, J., et al.: Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. *AMA Oncol*, 2016, 2, s. 313–320.
- Kuan, F. C. – Kuo, L. T. – Chen, M. C., et al.: Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. *Br J Cancer*, 2015, 113, s. 1519–1528.
- Meisel, A. – Hochmair, M.: Critical review of EGFR-mutated NSCLC: what we do and do not know. *Březien 2020. Healthbook TIMES Oncology Hematology*, DOI:10.36000/hbT.OH.2020.03.012.
- Conforti, F. – Pala, L. – Bagnardi, V., et al.: EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non-small cell lung cancer: a meta-analysis of randomized clinical trials. *JNCI Cancer Spectrum*, 2020, 4, s. pkaa064.
- Papadimitrakopoulou, V. A. – Mok, T. S. – Han, J.-Y., et al.: Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. *Ann Oncol*, 2020, 31, s. 1536–1544.
- Soria, J. C. – Ohe, Y. – Vansteenkiste, J., et al.: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 113–125.
- Hochmair, M. J. – Morabito, A. – Hao, D., et al.: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. *Future Oncol*, 2020, 16, s. 2799–2808.
- Ito, K. – Morise, M. – Wakuda, K., et al.: A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CLSG1903. *ESMO Open*, 2021, 6, s. 100115.
- Akamatsu, H. – Toi, Y. – Hayashi, H., et al.: Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor–tyrosine kinase inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. *JAMA Oncol*, 2021, 7, s. 386–394.
- Herbst, R. S. – Tsuboi, M. – John, T., et al.: Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive NSCLC after complete tumor resection. *J Clin Oncol*, 2020, 38, suppl. 18, LBAS-LBAS.
- Park, K. – Haura, E. B. – Leighl, N. B., et al.: Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. *J Clin Oncol*, 2021, 39, s. 3391–3402.
- Riely, G. J. – Neal, J. W. – Camidge, D. R., et al.: Updated results from a phase 1/2 study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions. In: *Sborník ESMO Virtual Congress 2020*, online, 19.–21. 9. 2020.
- Bílek, O. – Holánek, M. – Berkovcová, J., et al.: Méně časté mutace EGFR v kontextu léčby nemalobuněčného karcinomu plic. *Klin Onkol*, 2019, 32, suppl. 3, s. 356–3512.
- Wang, S. – Yan, B. – Zhang, Y., et al.: Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. *Int J Cancer*, 2019, 144, s. 2880–2886.
- Du, X. – Yang, B. – An, Q., et al.: Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. *Innovation*, 2021, 2, s. 100103.
- Hallberg, B. – Palmer, R. H.: The role of the ALK receptor in cancer biology. *Ann Oncol*, 2016, 27, suppl. 3, s. iii4–iii15.
- Du, X. – Shao, Y. – Qin, H. F., et al.: ALK-rearrangement in non-small-cell lung cancer (NSCLC). *Thorac Cancer*, 2018, 9, s. 423–430.
- Hofman, P.: ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. *Cancers*, 2017, 9, s. 107.
- Shaw, A. T. – Yeap, B. Y. – Mino-Kenudson, M., et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol*, 2009, 27, s. 4247–4253.
- Shaw, A. T. – Dong-Wan, K. – Nakagawa, K., et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*, 2013, 368, s. 2385–2394.
- Solomon, B. J. – Mok, T. – Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*, 2014, 371, s. 2167–2177.
- Lin, J. J. – Riely, G. J. – Shaw, A. T.: Targeting ALK: precision medicine takes on drug resistance. *Cancer Discov*, 2017, 7, s. 37–155.
- Gainor, J. F. – Dardaei, L. – Yoda, S., et al.: Molecular mechanisms of resistance to first and second generation ALK inhibitors in ALK-rearranged lung cancer. *Cancer Discov*, 2016, 6, s. 1118–1133.
- Kim, D. W. – Mehra, R. – Tan, D. S. W., et al.: Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol*, 2016, 17, s. 452–463.
- Crinò, L. – Ahn, M. J. – De Marinis, F., et al.: Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. *J Clin Oncol*, 2016, 34, s. 2866–2873.
- Nishio, M. – Felip, E. – Orlov, S., et al.: Final overall survival and other efficacy and safety results from ASCEND-3: phase II study of ceritinib in ALK-naïve patients with alk-rearranged NSCLC. *J Thorac Oncol*, 2020, 15, s. 609–617.
- Soria, J. C. – Tan, D. S. W. – Chiari, R., et al.: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. *Lancet*, 2017, 389, s. 917–929.
- Shaw, A. T. – Kim, T. M. – Crinò, L., et al.: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet*, 2017, 18, s. 874–886.
- Yoshioka, H. – Hida, T. – Nokihara, H., et al.: Final OS analysis from the phase III a-lex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). *J Clin Oncol*, 2021, 39, suppl. 15, s. 9022–9022.
- Peters, S. – Mok, T. S. K. – Gadgil, S. M., et al.: Updated overall survival (OS) and safety data from the randomized, phase III ALEX study

- of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. *J Clin Oncol*, 2020, 38, s. 9518.
- 40 Kim, D. W. – Tiseo, M. – Ahn, M. J., et al.: Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. *J Clin Oncol*, 2017, 35, s. 2490–2498.
 - 41 Camidge, D. R. – Kim, H. R. – Ahn, M. J., et al.: Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. *J Clin Oncol*, 2020, 38, s. 3592–3603.
 - 42 Yang, Y. – Zhou, J. – Zhou, J., et al.: Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. *Lancet Respir Med*, 2020, 8, s. 45–53.
 - 43 Horn, L. – Wang, Z. – Wu, G., et al.: Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. *JAMA Oncol*, 2021, 7, s. 1617–1625.
 - 44 Solomon, B. J. – Besse, B. – Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. *Lancet Oncol*, 2018, 19, s. 1654–1667.
 - 45 Shaw, A. T. – Bauer, T. M. – de Marinis, F., et al.: First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. *N Engl J Med*, 2020, 383, s. 2018–2029.
 - 46 Song, X. – Zhong, H. – Qu, X., et al.: Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras. *MedComm*, 2021, 2, s. 341–350.
 - 47 Sehgal, K. – Patel, R. – Rangachari, D., et al.: Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. *Transl Cancer Res*, 2018, 7, suppl. 7, s. S779–S786.
 - 48 Shaw, A. T. – Ou, S. H. – Bang, Y. J., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 371, s. 1963–1971.
 - 49 Shaw, A. T. – Riehl, G. J. – Bang, Y. J., et al.: Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001. *Ann Oncol*, 2019, 30, s. 1121–1126.
 - 50 Michels, S. – Massuti, B. – Schildhaus, H. U., et al.: Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European Phase II Clinical Trial. *J Thorac Oncol*, 2019, 14, s. 1266–1276.
 - 51 Moro-Sibilot, D. – Cozic, N. – Perol, M., et al.: Crizotinib in c-MET- or ROS1-positive NSCLC: Results of the AcSe phase II trial. *Ann Oncol*, 2019, 30, s. 1985–1991.
 - 52 Lim, S. M. – Kim, H. R. – Lee, J. S., et al.: Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. *J Clin Oncol*, 2017, 35, s. 2613–2618.
 - 53 Drilon, A. – Siena, S. – Dziadziuszko, R., et al.: Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (korekce in: *Lancet Oncol*, 2020, 21, s. e70; *Lancet Oncol*, 2020, 21, s. e341). *Lancet Oncol*, 2020, 21, s. 261–270.
 - 54 O'Leary, C. – Andelkovic, V. – Ladwa, R., et al.: Targeting BRAF mutations in non-small cell lung cancer. *Translational Lung Cancer Research*, 2019, 8, s. 1119–1124.
 - 55 Mazieres, J. – Cropet, C. – Montane, L., et al.: Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. *Ann Oncol*, 2020, 31, s. 289–294.
 - 56 Planchard, D. – Besse, B. – Groen, H.: Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (mut) metastatic non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2020, 38, suppl. 15, s. 9593.
 - 57 Strohmeier, S. – Brcic, I. – Popper, H., et al.: Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma. *Sci Rep*, 2021, 11, s. 9785.
 - 58 Russo, A. – Lopes, A. R. – Scilla, K., et al.: NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC). *Precis Cancer Med*, 2020, 3, s. 14.
 - 59 Hong, D. S. – DuBois, S. G. – Kummer, S., et al.: Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol*, 2020, 21, s. 531–540.
 - 60 Dziadziuszko, R. – Krebs, M. G. – DeBraud, F., et al.: Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. *J Clin Oncol*, 2021, 39, s. 1253–1263.
 - 61 Skoulidis, F. – Li, B. T. – Dy, G. K., et al.: Sotorasib for lung cancers with KRAS p.G12C mutation. *N Engl J Med*, 2021, 384, s. 2371–2381.
 - 62 Riely, G. J. – Ou, S. I. – Rybkin, I., et al.: KRYSTAL-1: Activity and pre-clinical pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation. European Lung Cancer Virtual Conference, 25–27. 3. 2021, abstrakt 990_PR.
 - 63 Lin, C. – Wang, S. – Xie, W., et al.: The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. *Cancer Biol Ther*, 2015, 16, s. 1019–1028.
 - 64 Drilon, A. – Lin, J. J. – Filleron, T., et al.: Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. *J Thorac Oncol*, 2018, 13, s. 1595–1601.
 - 65 Yanagitani, N. – Takeuchi, S. – Murayama, T., et al.: Alectinib in previously treated RET-rearranged advanced non-small-cell lung cancer: a phase 1/2 trial (ALL-RET). *J Thorac Oncol*, 2019, 14, s. S207.
 - 66 Drilon, A. – Fu, S. – Patel, M. R., et al.: A phase I/IIb trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105. *Cancer Discov*, 2019, 9, s. 384–395.
 - 67 Drilon, A. – Oxnard, G. R. – Tan, D. S. W., et al.: Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. *N Engl J Med*, 2020, 383, s. 813–824.
 - 68 Gainor, J. F. – Curigliano, G. – Kim, D. W., et al.: Registrational dataset from the phase III ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2020, 38, s. 9515.
 - 69 Subbiah, V. – Gainor, J. F. – Oxnard, G. R., et al.: Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. *J Clin Oncol*, 2020, 38, s. 9516.
 - 70 Zhao, J. – Xia, Y.: Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review. *JCO Precision Oncology*, 2020, 4, s. 411–425.
 - 71 Mazieres, J. – Barlesi, F. – Filleron, T., et al.: Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol*, 2016, 27, s. 281–286.
 - 72 Li, B. T. – Michelini, F. – Misale, S., et al.: HER2-mediated internalization of cytotoxic agents in ERBB2/amplified or mutant lung cancers. *Cancer Discov*, 2020, 10, s. 674–687.
 - 73 Peters, S. – Stahel, R. – Bubendorf, L., et al.: Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. *Clin Cancer Res*, 2019, 25, s. 64–72.
 - 74 Smit, E. F. – Nakagawa, K. – Nagasaka, M., et al.: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. *J Clin Oncol*, 2020, 38, s. 9504.
 - 75 Tsurutani, J. – Iwata, H. – Krop, I., et al.: Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. *Cancer Discov*, 2020, 10, s. 688–701.
 - 76 Elamin, Y. Y. – Robichaux, J. P. – Carter, B. W., et al.: Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase II trial. *J Clin Oncol*, 2021, DOI: 10.1200/JCO.21.01113.
 - 77 Liu, S. – Villaruz, L. C. – Lee, V. H. F., et al.: First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. ESMO Virtual Congress, online 19–21. 9. 2020.
 - 78 Tong, J. H. – Yeung, S. F. – Chung, L. Y., et al.: MET Amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. *Clin Cancer Res*, 2016, 22, s. 3048–3056.
 - 79 Bubendorf, L. – Dafni, U. – Schöbel, M., et al.: Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. *Lung Cancer*, 2017, 111, s. 143–149.
 - 80 Drilon, A. – Clark, J. W. – Weiss, J., et al.: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. *Nat Med*, 2020, 26, s. 47–51.
 - 81 Camidge, D. R. – Ou, S. H. – Shapiro, G., et al.: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2014, 32, s. 8001.
 - 82 Wolf, J. – Seto, T. – Han, J. Y., et al.: Capmatinib in MET/ exon 14-mutated or MET-amplified non-small-cell lung cancer. *N Engl J Med*, 2020, 383, s. 944–957.
 - 83 Paik, P. K. – Felip, E. – Veillon, R., et al.: Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. *N Engl J Med*, 2020, 383, s. 931–943.
 - 84 Lu, S. – Fang, J. – Li, X., et al.: Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). *J Clin Oncol*, 2020, 38, s. 9519.
 - 85 Pakkala, S. – Ramalingam, S. S.: Personalized therapy for lung cancer: striking a moving target. *JCI Insight*, 2018, 3, s. e120858.

Entrectinib v léčbě ROS1 pozitivního pokročilého nemalobuněčného plicního karcinomu a v léčbě solidních nádorů s NTRK fúzí

MUDr. Petra Zemanová Onkologická klinika, Klinika tuberkulózy a respiračních onemocnění VFN a 1. LF UK, Praha

doc. MUDr. Milada Zemanová, Ph.D. | prof. MUDr. Luboš Petruželka, CSc. | MUDr. Jan Špaček, Ph.D. Onkologická klinika VFN

a 1. LF UK, Praha doc. MUDr. Jiří Votruba, Ph.D. Klinika tuberkulózy a respiračních onemocnění VFN a 1. LF UK, Praha

- 1 Farago, A. F. – Taylor, M. S. – Doebele, R. C., et al.: Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. *JCO Precis Oncol*, 2018, 2018:PO.18.00037.
- 2 Roskoski, R. Jr.: ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. *Pharmacol Res*, 2017, 121, s. 202–212.
- 3 Davare, M. A. – Vellore, N. A. – Wagner, J. P., et al.: Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. *Proc Natl Acad Sci U S A*, 2015, 112, s. E5381–5390.
- 4 Davies, K. D. – Le, A. T. – Theodorou, M. F., et al.: Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. *Clin Cancer Res*, 2012, 18, s. 4570–4579.
- 5 D'Angelo, A. – Sobhani, N. – Chapman, R., et al.: Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies. *Cancers*, 2020, 12, s. 3293.
- 6 Patil, T. – Smith, D. E. – Bunn, P. A., et al.: The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. *J Thorac Oncol*, 2018, 13, s. 1717–1726.
- 7 Liang, Y. – Wakelee, H. A. – Neal, J. W.: Relationship of driver oncogenes to long-term pemetrexed response in non-small-cell lung cancer. *Clin Lung Cancer*, 2015, 16, s. 366–373.
- 8 Song, Z. – Su, H. – Zhang, Y.: Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. *Cancer Med*, 2016, 5, s. 2688–2693.
- 9 Mazieres, J. – Drilon, A. – Lusque, A., et al.: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol*, 2019, 30, s. 1321–1328.
- 10 Dziadziuszko, R. – Krebs, M. G. – De Braud, F., et al.: Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. *J Clin Oncol*, 2021, 39, s. 1253–1263.
- 11 Skaper, S. D.: The neurotrophin family of neurotrophic factors: an overview. *Methods Mol Biol*, 2012, 846, s. 1–12.
- 12 Stransky, N. – Cerami, E. – Schalm, S., et al.: The landscape of kinase fusions in cancer. *Nat Commun*, 2014, 5, s. 4846.
- 13 Cocco, E. – Scaltriti, M. – Drilon, A.: NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol*, 2018, 15, s. 731–747.
- 14 Haratake, N. – Seto, T.: NTRK Fusion-positive non-small-cell lung cancer: the diagnosis and targeted therapy. *Clin Lung Cancer*, 2021, 22, s. 1–5.
- 15 Rolfo, Ch. D. – De Braud, F. G. – Doebele, R. C., et al.: Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis. *J Clin Oncol*, 2020, 38, suppl. 15, s. 3605–3605.
- 16 John, T. – Chiu, C. H. – Cho, B., et al.: 3640 – Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. *Ann Oncol*, 2020, 31, suppl. 4, s. S396–S408. 10.1016/annonc/annonc269.

Leuprorelin v léčbě karcinomu prostaty

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Ferlay, J. – Soerjomataram, I. – Dikshit, R., et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 2015, 136, s. E359–E386.
- 2 Bell, K. J. – Del, M. C. – Wright, G., et al.: Prevalence of incidental prostate cancer: A systematic review of autopsy studies. *Int J Cancer*, 2015, 137, s. 1749–1757.
- 3 Haas, G. P. – Delongchamps, N. – Brawley, O. W., et al.: The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. *Can J Urol*, 2008, 15, s. 3866–3871.
- 4 Mottet, N. – van den Bergh, R. C. N. – Briers, E., et al.: EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer – 2020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent. *Eur Urol*, 2021, 79, s. 243–262.
- 5 Oefelein, M. G. – Feng, A. – Scolieri, M. J., et al.: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. *Urology*, 2000, 56, s. 1021–1024.
- 6 Klotz, L. – Boccon-Gibod, L. – Shore, N. D., et al.: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int*, 2008, 102, s. 1531–1538.
- 7 Saltzstein, D. – Shore, N. D. – Moul, J. W., et al.: Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. *Ther Adv Urol*, 2018, 10, s. 43–50.
- 8 Perez-Marreno, R. – Chu, F. M. – Gleason, D., et al.: A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. *Clin Ther*, 2002, 24, s. 1902–1914.
- 9 Persad, R.: Leuprorelin acetate in prostate cancer: a European update. *Int J Clin Pract*, 2002, 56, s. 389–396.
- 10 Sennello, L. T. – Finley, R. A. – Chu, S. Y., et al.: Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. *J Pharm Sci*, 1986, 75, s. 158–160.
- 11 Chu, F. M. – Jayson, M. – Dineen, M. K., et al.: A clinical study of 22.5 mg La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. *J Urol*, 2002, 168, s. 1199–1203.
- 12 Sartor, O.: Eligard: leuprolide acetate in a novel sustained-release delivery system. *Urology*, 2003, 61, s. 25–31.
- 13 Crawford, E. D. – Sartor, O. – Chu, F., et al.: A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. *J Urol*, 2006, 175, s. 533–536.
- 14 Tunn, U. W.: A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. *BMC Urol*, 2011, 11, s. 15.
- 15 Ohlmann, C. H. – Gross-Langenhoff, M.: Efficacy and tolerability of leuprorelin acetate (Eligard®) in daily practice in Germany: pooled data from 2 prospective, non-interventional studies with 3- or 6-month depot formulations in patients with advanced prostate cancer. *Urol Int*, 2018, 100, s. 66–71.
- 16 Bertaglia, V. – Tucci, M. – Fiori, C., et al.: Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. *Clin Genitourin Cancer*, 2013, 11, s. 325–330.
- 17 Klotz, L. – O'Callaghan, C. – Ding, K., et al.: Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. *J Clin Oncol*, 2015, 33, s. 1151–1156.
- 18 Pieczonka, C. M. – Twardowski, P. – Renzulli, J., et al.: Effectiveness of subcutaneously administered leuprolide acetate to achieve low nadir testosterone in prostate cancer patients. *Rev Urol*, 2018, 20, s. 63–68.
- 19 Ozyigit, G. – Akoyol, F.: Cost-effectiveness analysis of leuprorelin acetate atrelig in the treatment of prostate cancer. *Turk J Oncol*, 2020, 35, s. 430–437.
- 20 www.uzis.cz

Sorafenib STADA 400 mg potahované tablety – lékový profil

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Forner, A. – Reig, M. – Bruix, J.: Hepatocellular carcinoma. *Lancet*, 2018, 391, s. 1301–1314.
- 2 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology*, 1998, 28, s. 751–755.
- 3 Liu, L. – Cao, Y. – Chen, C., et al.: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. *Cancer Res*, 2006, 66, s. 11851–11858.
- 4 Sorafenib STADA 400 mg potahované tablety. SPC, www.sukl.cz.
- 5 Abou-Alfa, G. K. – Schwartz, L. – Ricci, S., et al.: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. *J Clin Oncol*, 2006, 24, s. 4293–4300.
- 6 Llovet, J. M. – Ricci, S. – Mazzaferro, V., et al.: Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*, 2008, 359, s. 378–390.
- 7 Cheng, A. L. – Kang, Y. K. – Chen, Z., et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*, 2009, 10, s. 25–34.
- 8 Raouf, J. – Santoro, A. – Beaugrand, M., et al.: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial. *J Clin Oncol*, 2008, 26S, ASCO #4587.
- 9 Huang, Y. – Cheng, X. – Sun, P., et al.: Supplementary sorafenib therapies for hepatocellular carcinoma – a systematic review and meta-analysis: supplementary sorafenib for liver cancer. *J Clin Gastroenterol*, 2019, 53, s. 486–494.
- 10 Escudier, B. – Eisen, T. – Stadler, W. M., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 125–134.
- 11 Liu, X. L. – Xue, H. Y. – Chu, Q., et al.: Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis. *Medicine*, 2020, 99, s. e19570.

Niraparib – zaměřeno na efektivní dávkování – souhrnné sdělení

MUDr. Josef Chovanec, Ph.D. | MUDr. Monika Náležinská Oddělení gynekologické onkologie, Klinika operační onkologie MOÚ a LF MU Brno

- 1 SVOD. Epidemiologie zhoubných nádorů v ČR. Aktualizace dat NOR za rok 218, dostupné online z: <https://www.svod.cz>.
- 2 Cibula, D. – Frůhauf, F. – Kocián, R., et al.: Cílená léčba ovariálního karcinomu. Webinář Onkogynekologického centra 1. LF UK a VFN v Praze. Dostupné z: <https://www.farmakoterapie.cz/online/2021/3:426-432>, vyhledáno 15. 11. 2021.
- 3 Zvariková, M. – Kristková, L.: Niraparib. *Remedia*, 2020, 30, s. 375–382.
- 4 Kocián, R. – Cibula, D.: Niraparib v léčbě ovariálního karcinomu. *Aktuální témata v onkologii*, 2021, 6, s. 27–29.
- 5 ESMO Clinical Practice Guidelines: Gynaecological Cancers. Dostupné z: www.esmo.org/guidelines/gynaecological-cancers, vyhledáno 15. 11. 2021.
- 6 Modrá kniha České onkologické společnosti. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/online-novelizace-dodatky/>, vyhledáno 15. 11. 2021.
- 7 Mirza, M. R. – Benigno, B. – Dorum, A., et al.: Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. *Gynecol Oncol*, 2020, 159, s. 442–448.
- 8 Matulonis, U. – Herrstedt, J. – Ozza, A., et al.: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. *Gynecologic Oncology*, 2021, 162, suppl. 1, s. S24–S25.
- 9 Vilming, B. – Fallås-Dahl, J. – Bentzen, A.-G.: Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer. *J Clin Oncol*, 2021, 39, suppl. 15, s. 5560–5560.
- 10 Lee, E. K. – Matulonis, U. A.: PARP inhibitor resistance mechanisms and implications for post-progression combination therapies. *Cancers*, 2020, 12, s. 2054.
- 11 Zikán, M.: Cílená léčba ovariálního karcinomu. *Acta Medicinæ*, 2021, 5–7, s. 14–20.
- 12 Moore, K. N. – Secord, A., et al.: Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRRRA): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*, 2019, 20, s. 636–648.
- 13 La Fargue, Ch. J. – Dal Molin, G. Z. – Sood, A. K., et al.: Exploring and comparing adverse events between PARP inhibitors. *Lancet Oncol*, 2019, 20, s. e15–e28.
- 14 Matulonis, U. A., et al.: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase 3 trial of niraparib in recurrent ovarian cancer. Prezentováno virtuálně na Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women's Cancer; 19.–21. 3. 2021, abstrakt 37.
- 15 González-Martin, A. – Pothuri, B. – Vergote, I., et al.: Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2019, 381, s. 2391–2402.

Lipozomálně vázaný irinotekan v onkologické léčbě

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Ventola, C. L.: Progress in nanomedicine: approved and investigational nanodrugs. *PT*, 2017, 42, s. 742–755.
- 2 Rosenblum, D. – Joshi, N. – Tao, W., et al.: Progress and challenges to ward targeted delivery of cancer therapeutics. *Nat Commun*, 2018, 9, s. 1410.
- 3 Sun, Q. – Kanehira, K. – Taniguchi, A.: PEGylated TiO₂ nanoparticles mediated inhibition of cell migration via integrin beta 1. *Sci Technol Adv Mater*, 2018, 19, s. 271–281.
- 4 Li, L. – Wang, J. – Kong, H., et al.: Functional biomimetic nanoparticles for drug delivery and the nanostic applications in cancer treatment. *Sci Technol Adv Mater*, 2018, 19, s. 771–790.
- 5 Kumari, A. – Singla, R. – Guliani, A., et al.: Nanoencapsulation for drug delivery. *EXCLI J*, 2014, 13, s. 265–286.
- 6 Abu Lila, A. S. – Ishida, T.: Liposomal delivery systems: design optimization and current applications. *Biol Pharm Bull*, 2017, 40, s. 1–10.
- 7 Ando, H. – Kobayashi, S. – Abu Lila, A. S., et al.: Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. *J Control Release*, 2015, 220, s. 29–36.
- 8 Lu, L. – Ding, Y. – Zhang, Y., et al.: Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII. *Int J Nanomedicine*, 2018, 13, s. 1927–1944.
- 9 Harris, J. M. – Chess, R. B.: Effect of pegylation on pharmaceuticals. *Nat Rev Drug Discov*, 2003, 2, s. 214–221.
- 10 Papahadjopoulos, D. – Allen, T. M. – Gabizon, A., et al.: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. *Proc Natl Acad Sci U S A*, 1991, 88, s. 11460–11464.
- 11 Kalra, A. V. – Kim, J. – Klinz, S. G., et al.: Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. *Cancer Res*, 2014, 74, s. 7003–7013.
- 12 Thomas, A. – Pommier, Y.: Targeting topoisomerase I in the era of precision medicine. *Clin Cancer Res*, 2019, 25, s. 6581–6589.
- 13 Ko, A. H. – Tempero, M. A. – Shan, Y. S., et al.: A multinational phase

- 2 study of nanoliposomal irinotecan sucros of ate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. *Br J Cancer*, 2013, 109, s. 920–925.
- 14 Wang-Gillam, A. – Li, C. P. – Bodoky, G., et al.: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet*, 2016, 387, s. 545–557.
- 15 Wang-Gillam, A. – Hubner, R. A. – Sivek, J. T., et al.: NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. *Eur J Cancer*, 2019, 108, s. 78–87.
- 16 Bang, Y. J. – Li, C. P. – Lee, K. H., et al.: Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. *Cancer Sci*, 2020, 111, s. 513–527.
- 17 Macarulla Mercadé, T. – Chen, L. T. – Li, C. P., et al.: Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. *Pancreas*, 2020, 49, s. 62–75.
- 18 Fleeman, N. – Abdulla, A. – Bagust, A., et al.: Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine: an evidence review group perspective of a NICE single technology appraisal. *Pharmacoeconomics*, 2018, 36, s. 289–299.
- 19 Frampton, J. E.: Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. *Drugs*, 2020, 80, s. 1007–1018.

Belantamab mafodotin, první protilátka konjugovaná s cytotoxickou látkou pro léčbu mnohočetného myelomu

MUDr. Zdeněk Kořístek, Ph.D. Klinika hematologické, Fakultní nemocnice Ostrava

- 1 Blenrep (belantamabum mafodotinum). Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv, srpen 2020. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_cs.pdf, vyhledáno 23. 11. 2021.
- 2 Lee, L. – Bounds, D. – Paterson, J., et al.: Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. *Br J Haematol*, 2016, 174, s. 911–922.
- 3 Nilsson, R. – Mårtensson, L. – Eriksson, S. E., et al.: Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model. *Cancer*, 2010, 116, suppl. 4, s. 1033–1042.
- 4 Tai, Y. T. – Mayes, P. A. – Acharya, C., et al.: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood*, 2014, 123, s. 3128–3138.
- 5 Trudel, S. – Lendvai, N. – Popat, R., et al.: Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. *Lancet Oncol*, 2018, 19, s. 1641–1653.
- 6 Trudel, S. – Lendvai, N. – Popat, R., et al.: Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose-expansion phase I study. *Blood Cancer J*, 2019, 9, s. 37.
- 7 Lonial, S. – Lee, H. C. – Badros, A., et al.: Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*, 2020, 21, s. 207–221.
- 8 Blenrep_LÉKAR – Edukační materiály pro lékaře. Dostupné z: <https://www.sukl.cz/leciva/em-belantamab>, vyhledáno 23. 11. 2021.
- 9 Lassiter, G. – Bergeron, C. – Guedry, R., et al.: Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects. *Curr Oncol*, 2021, 28, s. 640–660.
- 10 Weisel, K. – Hopkins, T. G. – Fecteau, D., et al.: DREAMM-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (pom/dex) in participants with relapsed/refractory multiple myeloma (RRMM). *Blood*, 2019, 134, s. 1900.
- 11 Trudel, S. – Nooka, A. – Fecteau, D., et al.: 1105TIP – DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). *Ann Oncol*, 2019, 20, suppl. 5, s. 447.
- 12 Nooka, A. K. – Weisel, K. – van de Donk, N. W., et al.: Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. *Future Oncol*, 2021, 17, s. 1987–2003.
- 13 Nooka, A. K. – Stockerl-Goldstein, K. – Quach, H., et al.: DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM) *J Clin Oncol*, 2020, 38, s. 8502.
- 14 Lonial, S., et al.: Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*, 2021, 127, s. 4198–4212.

Inovativní přístupy v léčbě atopické dermatitidy – méně specifická cílená léčba, nebo biologická léčba „šitá na míru“?

prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA Dermatovenerologická klinika FN KV, Praha

- 1 Kowalska-Oleđzka, E. – Czarnicka, M. – Baran, A.: Epidemiology of atopic dermatitis in Europe. *J Drug Assess*, 2019, 8, s. 126–128.
- 2 Shrestha, S. – Miao, R. – Wang, L., et al.: Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, medicare, and medical databases. *Adv Ther*, 2017, 34, s. 1989–2006.
- 3 Barbarot, S. – Auziere, S. – Gadkari, A., et al.: Epidemiology of atopic dermatitis in adults: Results from an international survey. *Allergy*, 2018, 73, s. 1284–1293.
- 4 Cheok, S. – Yee, F. – Song, J. Y., et al.: Prevalence and descriptive epidemiology of atopic dermatitis and its impact on quality of life in Singapore. *BJD*, 2018, 178, s. 276–277.
- 5 Narala, S. – Hata, T. R.: Adult atopic dermatitis with comorbid atopic disease is associated with increased risk of infections: a population-based cross-sectional study. *Dermatol Ther*, 2017, 7, s. 111–121.
- 6 Silverwood, R. J. – Forbes, H. J. – Abuabara, K., et al.: Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. *BMJ*, 2018, 361, s. k1786.
- 7 Schmitt, J. – Schwarz, K. – Baurecht, H., et al.: Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. *J Allergy Clin Immunol*, 2016, 137, s. 130–136.
- 8 Drucker, A. M. – Qureshi, A. A. – Amand, C., et al.: Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. *J Allergy Clin Immunol In Practice*, 2018, 6, s. 1342–1348.
- 9 Wollenberg, A. – Barbarot, S. – Bieber, T., et al.: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol*, 2018, 32, s. 657–682.
- 10 Simpson, E. L. – Guttman-Yassky, E. – Margolis, D. J., et al.: Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. *JAMA Dermatol*, 2018, 154, s. 903–912.
- 11 Bieber, T.: Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. *Nat Rev Drug Discov*, 2021, dostupné z: <https://doi.org/10.1038/s41573-021-00266-6>, vyhledáno 27. 10. 2021.
- 12 Plant, A. – Ardern-Jones, M. R.: Advances in atopic dermatitis. *Clin Med*, 2021, 21, s. 177–181.
- 13 Munera-Campos, M. – Carrascosa, J. M.: Innovation in atopic dermatitis: from pathogenesis to treatment. *Actas Dermosifiliogr*, 2020, 111, s. 205–221.
- 14 Carr, W. W.: Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. *Paediatr Drugs*, 2013, 15, s. 303–310.
- 15 Paller, A. S. – Fölster-Holst, R. – Chen, S. C., et al.: No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. *J Am Acad Dermatol*, 2020, 83, s. 375–381.
- 16 Seger, E. W. – Wechter, T. – Strowd, L., et al.: Relative efficacy of systemic treatments for atopic dermatitis. *J Am Acad Dermatol*, 2019, 80, s. 411–416.e4.
- 17 Bußmann, C. – Novak, N.: Systemic therapy of atopic dermatitis. *Allergol Select*, 2017, 1, s. 1–8.
- 18 Böhm, I. – Bauer, R.: Th1-Zellen, Th2-Zellen und atopische Dermatitits. *Hautarzt*, 1997, 48, s. 223–227.
- 19 Worm, M. – Francuzik, W. – Kraft, M., et al.: Modern therapies in atopic dermatitis: biologics and small molecule drugs. *J Dtsch Dermatol Ges*, 2020, 18, s. 1085–1092.
- 20 Zhou, S. – Qi, F. – Gong, Y., et al.: Biological therapies for atopic dermatitis: a systematic review. *Dermatology*, 2021, 237, s. 542–552.
- 21 Silverberg, J. – Toth, D. – Bieber, T., et al.: Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. *Br Jo Dermatol*, 2021, 184, s. 450–463.
- 22 Guttman-Yassky, E. – Teixeira, H. D. – Simpson, E. L., et al.: Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet*, 2021, 397, s. 2151–2168.
- 23 Reich, K. – Teixeira, H. D. – Bruin-Weller, M., et al.: Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2021, 397, s. 2169–2181.
- 24 Thyssen, J. P. – Thomsen, S. F.: Treatment of atopic dermatitis with biologics and Janus kinase inhibitors. *Lancet*, 2021, 397, s. 2126–2128.
- 25 MedChemExpress. JAK/STAT Compound Library. Dostupné z: <https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk>, vyhledáno 27. 10. 2021.
- 26 PRAC recommendations on signals. Adopted at the 7-10 June 2021 PRAC meeting, s. 13. EMA/PRAC/319259/2021. Dostupné z: <https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-june-2021-prac-meeting.pdf>, vyhledáno 27. 10. 2021.